Raised circulating tenascin-C in rheumatoid arthritisReport as inadecuate




Raised circulating tenascin-C in rheumatoid arthritis - Download this document for free, or read online. Document in PDF available to download.

Arthritis Research and Therapy

, 14:R260

First Online: 29 November 2012Received: 11 July 2012Revised: 23 November 2012Accepted: 28 November 2012

Abstract

IntroductionThe aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C TNC are elevated in musculoskeletal disorders including rheumatoid arthritis RA and to assess in RA whether levels are related to clinical disease status and-or patient response to treatment.

MethodsTNC in serum or plasma was quantified by ELISA. Samples from 4 cohorts of RA patients were examined and compared to normal human subjects and to patients with other inflammatory diseases.

ResultsCirculating TNC levels were significantly raised in patients with RA, as well as patients with systemic lupus erythematosus, idiopathic inflammatory myositis, psoriatic arthritis and ankylosing spondylitis, whilst patients with Sjogren-s syndrome displayed levels similar to healthy controls. The highest levels of TNC were observed in RA patients with late stage disease. In early disease TNC levels correlated positively with ultrasound determined erosion scores. Treatment of early RA patients with infliximab plus methotrexate MTX resulted in a transient decrease in circulating TNC over the first year of therapy. In contrast, TNC levels increased over time in RA patients receiving MTX alone. In patients treated with infliximab plus MTX, baseline TNC levels significantly correlated with tender joint counts TJC at 18 and 54 weeks after initiation of infliximab therapy.

ConclusionsRaised circulating TNC levels are detected in specific inflammatory diseases. Levels are especially high in RA where they may act as a biomarker of bone erosion and a predictor of the effect of infliximab on RA patient joint pain.

AbbreviationsACRAmerican College of Rheumatology

ASankylosing spondylitis

CRPC-reactive protein

anti-CCPanti-cyclic citrullinated peptide antibody

BIDbis in die twice daily

COMPcartilage oligomeric matrix protein

CPIItype II pro collagen

C2Cmarker of type II collagen cleavage

DAMPdamage-associated molecular pattern

DAS28disease activity score 28

DMARDdisease-modifying anti-rheumatic drug

ECMextracellular matrix

ELISAenzyme-linked immunosorbent assay

ESRerythrocyte sedimentation rate

IBDirritable bowel disease

IIMidiopathic inflammatory myositis

ILinterleukin

MTXmethotrexate

OAosteoarthritis

PIIINPprocollagen III N-terminal propeptide

PSApsoriatic arthritis

RArheumatoid arthritis

SLEsystemic lupus erythematosus

SSSjogren-s syndrome

SJCswollen joint count

TJCtender joint count

TLRtoll-like receptor

TNCtenascin-C

TNFtumour necrosis factor

TNIIIfibronectin type III-like repeats

UCulcerative colitis.

Electronic supplementary materialThe online version of this article doi:10.1186-ar4105 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Theresa H Page - Peter J Charles - Anna M Piccinini - Vicky Nicolaidou - Peter C Taylor - Kim S Midwood

Source: https://link.springer.com/







Related documents